Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India
ConclusionAt the current WTP threshold of one-time per capita GDP ( ₹ 146,890) of India, VRd alone and VRd plus AHSCT has 38.1% and 6.9% probability to be cost-effective, respectively. Reduction in current reimbursement rates of novel drugs, namely VRd, lenalidomide, and pomalidomide plus dexamethasone under national insurance program and societal cost of transpla nt by 50%, would make VRd plus AHSCT and VTd plus AHSCT cost-effective at an incremental cost of ₹40,671 (US$34) and ₹97,639 (US$1,281) per QALY gained, respectively.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Dexamethasone | Economics | Health Management | India Health | Insurance | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Transplants | Velcade